229 related articles for article (PubMed ID: 12651270)
1. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients.
Carreras E; Saiz A; Marín P; Martínez C; Rovira M; Villamor N; Aymerich M; Lozano M; Fernández-Avilés F; Urbano-Izpizua A; Montserrat E; Graus F
Haematologica; 2003 Mar; 88(3):306-14. PubMed ID: 12651270
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
3. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
[TBL] [Abstract][Full Text] [Related]
4. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation.
Statkute L; Verda L; Oyama Y; Traynor A; Villa M; Shook T; Clifton R; Jovanovic B; Satkus J; Loh Y; Quigley K; Yaung K; Gonda E; Krosnjar N; Spahovic D; Burt RK
Bone Marrow Transplant; 2007 Mar; 39(6):317-29. PubMed ID: 17277794
[TBL] [Abstract][Full Text] [Related]
5. [A prospective and randomized study of two conditioning regimens in treatment of severe systemic autoimmune diseases with autologous peripheral blood stem cell transplantation].
Zhang W; Zhou DB; Zhao Y; Leng XM; Zhang JP; Jiang Y; Jiao L; Wang SJ; Duan MH; Tang FL; Shen T
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1689-92. PubMed ID: 17825150
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis.
Xu J; Ji BX; Su L; Dong HQ; Sun XJ; Liu CY
Chin Med J (Engl); 2006 Nov; 119(22):1851-5. PubMed ID: 17134581
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
8. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
9. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis].
Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F
Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717
[TBL] [Abstract][Full Text] [Related]
10. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
11. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients.
Burt RK; Traynor AE; Cohen B; Karlin KH; Davis FA; Stefoski D; Terry C; Lobeck L; Russell EJ; Goolsby C; Rosen S; Gordon LI; Keever-Taylor C; Brush M; Fishman M; Burns WH
Bone Marrow Transplant; 1998 Mar; 21(6):537-41. PubMed ID: 9543056
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
Fassas A; Passweg JR; Anagnostopoulos A; Kazis A; Kozak T; Havrdova E; Carreras E; Graus F; Kashyap A; Openshaw H; Schipperus M; Deconinck E; Mancardi G; Marmont A; Hansz J; Rabusin M; Zuazu Nagore FJ; Besalduch J; Dentamaro T; Fouillard L; Hertenstein B; La Nasa G; Musso M; Papineschi F; Rowe JM; Saccardi R; Steck A; Kappos L; Gratwohl A; Tyndall A; Samijn J;
J Neurol; 2002 Aug; 249(8):1088-97. PubMed ID: 12195460
[TBL] [Abstract][Full Text] [Related]
14. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients.
Ni XS; Ouyang J; Zhu WH; Wang C; Chen B
Clin Transplant; 2006; 20(4):485-9. PubMed ID: 16842526
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
Ballova V; Ladicka M; Vranovsky A; Lakota J
Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
[TBL] [Abstract][Full Text] [Related]
16. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
Villela L; Sureda A; Canals C; Sanz MA; Martino R; Valcárcel D; Altés A; Briones J; Gómez M; Brunet S; Sierra J
Haematologica; 2003 Mar; 88(3):300-5. PubMed ID: 12651269
[TBL] [Abstract][Full Text] [Related]
17. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.
Cassinotti A; Annaloro C; Ardizzone S; Onida F; Della Volpe A; Clerici M; Usardi P; Greco S; Maconi G; Porro GB; Deliliers GL
Gut; 2008 Feb; 57(2):211-7. PubMed ID: 17895357
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Xu J; Ji BX; Su L; Dong HQ; Sun WL; Wan SG; Liu YO; Zhang P; Liu CY
Ann Hematol; 2011 Mar; 90(3):343-8. PubMed ID: 20872003
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
20. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
